Ian M. Thompson

The University of Texas at San Antonio Health Science Center

Also affiliated with Christus Santa Rosa Health System

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.914Author DataRank

Indexed papers

5in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-20-0275

Top 33%

0.600DataRank

Top 33%10 citations

Lai Jiang, Rachael Z. Stolzenberg‐Solomon, Alan A. Arslan, Laura E. Beane Freeman, Paige M. Bracci +66 more

Papers

Driven by 75 papers — median percentile 0. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

European Urology(2023)10.1016/j.eururo.2023.08.004

N/A

2.9DataRank · unranked

93 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance +10 more

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-2409

N/A

2.8DataRank · unranked

92 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia +12 more

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer

New England Journal of Medicine(2024)10.1056/nejmoa2401497

N/A

2.4DataRank · unranked

64 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Nature Genetics(2021)10.1038/s41588-020-00748-0

N/A

0.934DataRank · unranked

504 citations

Burcu F. Darst, Lilit C. Moss, Edward J. Saunders, Xin Sheng, Alisha Chou +95 more

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

European Urology(2023)10.1016/j.eururo.2023.06.014

N/A

0.650DataRank · unranked

20 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

Genetically adjusted PSA levels for prostate cancer screening

Nature Medicine(2023)10.1038/s41591-023-02277-9

N/A

0.650DataRank · unranked

75 citations

Thomas J. Hoffmann, Yu Jiang, Sonja I. Berndt, John P. Shelley, Kerry Schaffer +18 more

Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-20-0275

Top 33%

0.600DataRank

Top 33%10 citations

Lai Jiang, Rachael Z. Stolzenberg‐Solomon, Alan A. Arslan, Laura E. Beane Freeman, Paige M. Bracci +66 more

Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis

Human Pathology(2022)10.1016/j.humpath.2022.01.009

N/A

0.489DataRank · unranked

25 citations

Yan Gao, Yi Ding, Ping Bu, Brian J. Miles, Angelo De Marzo +25 more

Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3

Cancer Research(2021)10.1158/0008-5472.can-20-3267

N/A

0.434DataRank · unranked

17 citations

Prosenjit Kundu, William Wheeler, Alan A. Arslan, Laura E. Beane-Freeman, Paige M. Bracci +72 more

Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk

Cancer Epidemiology Biomarkers & Prevention(2020)10.1158/1055-9965.epi-20-0651

N/A

0.406DataRank · unranked

14 citations

Jingjing Zhu, Wei Zheng, Jirong Long, Harvey J. Murff, Fei Ye +71 more

Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups

Nature Genetics(2025)10.1038/s41588-024-02068-z

N/A

0.385DataRank · unranked

12 citations

Rebecca E. Graff, Ravi Madduri, Alex A Rodriguez, Clinton L. Cario, Kun-Jiang Feng +44 more

Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk

Cancer Research(2020)10.1158/0008-5472.can-20-0447

N/A

0.345DataRank · unranked

9 citations

Rayjean J. Hung, Naomi Walsh, Han Zhang, Elizabeth A. Platz, William Wheeler +69 more

Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study

Modern Pathology(2023)10.1016/j.modpat.2023.100241

N/A

0.330DataRank · unranked

8 citations

Stephanie A. Harmon, Rachael Iseman, Olga Ludkowski, Heidi Auman, Sarah T. Hawley +28 more

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5070

N/A

0.330DataRank · unranked

8 citations

Akash Roy, Siyuan S Guo, Larysa Rydzewska, Peter J. Godolphin, Maha Hussain +15 more

African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

medRxiv(2020)10.1101/2020.04.20.20072926

Top 54%

0.314DataRank

Top 54%6 citations

Minh‐Phuong Huynh‐Le, Chun Chieh Fan, Wesley Thompson, Rosalind A. Eeles, Zsofia Kote‐Jarai +41 more

Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4506

N/A

0.312DataRank · unranked

7 citations

Melissa Plets, Gareth Morrison, Alexander Cunha, Steven Cen, Suhn K. Rhie +11 more

Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization

Cancer Epidemiology Biomarkers & Prevention(2023)10.1158/1055-9965.epi-23-0453

N/A

0.292DataRank · unranked

6 citations

Swathi Veliginti, Martijn C.G.J. Brouwers, Zhewen Ren, Wei Zheng, Veronica Wendy Setiawan +72 more

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00813-3

N/A

0.241DataRank · unranked

4 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4546

N/A

0.193DataRank · unranked

2 citations

Catherine M. Tangen, Christopher W. Ryan, Ulka N. Vaishampayan, Brian Shuch, Pedro C. Barata +7 more

Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma

British Journal of Urology(2024)10.1111/bju.16403

N/A

0.104DataRank · unranked

1 citations

Catherine M. Tangen, Melissa Plets, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey +11 more

Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4522

N/A

0DataRank · unranked

5 citations

Catherine M. Tangen, Michal Sarfaty, Ashley Marie Regazzi, I-Ling C. Lee, Woonyoung Choi +6 more

Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5071

N/A

0DataRank · unranked

2 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps591

N/A

0DataRank · unranked

1 citations

Melissa Plets, Michael A. Liss, Joshua J. Meeks, Daniel P. Petrylak, Suzanne Cole +9 more

Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry

European Urology(2023)10.1016/j.eururo.2023.01.022

N/A

0DataRank · unranked

51 citations

Ravi Madduri, Alex A Rodriguez, Burcu F. Darst, Alisha Chou, Xin Sheng +95 more

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0602

N/A

0DataRank · unranked

19 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +12 more

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

European Urology(2023)10.1016/j.eururo.2023.03.036

N/A

0DataRank · unranked

10 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +11 more

Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment

Translational Psychiatry(2023)10.1038/s41398-023-02600-5

N/A

0DataRank · unranked

5 citations

Yidong Chen, Jonathan Gelfond, Teresa L. Johnson‐Pais, Robin J. Leach, Chethan Ramamurthy +3 more

SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4508

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5080

N/A

0DataRank · unranked

2 citations

Catherine M. Tangen, Melissa Plets, Daniel Bsteh, Tong Xu, Jacek Pinski +13 more

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5074

N/A

0DataRank · unranked

2 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Yeonjung Jo, Andrea Harzstark +15 more

Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4562

N/A

0DataRank · unranked

1 citations

Catherine M. Tangen, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey, Adebowale Adeniran +9 more

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps581

N/A

0DataRank · unranked

0 citations

Melissa Plets, Primo N. Lara, Catherine M. Tangen, Rick Bangs, Seth P. Lerner +4 more

Data from Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial

(2023)10.1158/1055-9965.c.6515155

N/A

0DataRank · unranked

0 citations

Cathee Till, Phyllis J. Goodman, Howard L. Parnes, William D. Figg, Demetrius Albanes +5 more

Data from Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent

(2023)10.1158/1055-9965.c.6514782.v1

Top 100%

0DataRank

Top 100%0 citations

Elaine Spangler, Stephen Gallagher, Christopher A. Haiman, Brian E. Henderson, William B. Isaacs +29 more

Data from Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3

(2023)10.1158/0008-5472.c.6513538.v1

Top 100%

0DataRank

Top 100%0 citations

Prosenjit Kundu, William Morton Wheeler, Alan A. Arslan, Laura E. Beane Freeman, Paige M. Bracci +72 more

Data from Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent

(2023)10.1158/1055-9965.c.6514782

Top 100%

0DataRank

Top 100%0 citations

Elaine Spangler, Stephen Gallagher, Christopher A. Haiman, Brian E. Henderson, William B. Isaacs +29 more

Data from Contacts with Macrophages Promote an Aggressive Nanomechanical Phenotype of Circulating Tumor Cells in Prostate Cancer

(2023)10.1158/0008-5472.c.6512932.v1

N/A

0DataRank · unranked

0 citations

Alessandra Cunsolo, Meizhen Chen, Yusheng Qian, Chun-Lin Lin, Chia‐Nung Hung +9 more

Data from Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial

(2023)10.1158/1055-9965.c.6515155.v1

N/A

0DataRank · unranked

0 citations

Cathee Till, Phyllis J. Goodman, Howard L. Parnes, William D. Figg, Demetrius Albanes +5 more

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5048

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4608

N/A

0DataRank · unranked

0 citations

Melissa Plets, Primo N. Lara, Catherine M. Tangen, Rick Bangs, Seth P. Lerner +4 more

HERCULES: A prostate cancer (PC) sequencing panel for parallel analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5036

N/A

0DataRank · unranked

0 citations

Jonathan D. Buckley, Dejerianne Ostrow, Jean‐Hugues Parmentier, Smruthi Maganti, Scott A. Mitchell +14 more

Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6532

N/A

0DataRank · unranked

0 citations

Umang Swami, Yeonjung Jo, Georges Gebrael, Benjamin Haaland, Shilpa Gupta +7 more

African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

UNC Libraries(2023)10.17615/9cy6-py31

N/A

0DataRank · unranked

0 citations

the PRACTICAL consortium, Anders M. Dale, G. Petrovics, Thérèse Truong, Phyllis J. Goodman +42 more

A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry

UNC Libraries(2023)10.17615/fjrp-xk90

N/A

0DataRank · unranked

0 citations

Shiv Srivastava, Marie‐Élise Parent, Peter E. Clark, Kosj Yamoah, Mark Sanderson +67 more

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.01535

N/A

0DataRank · unranked

29 citations

Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter J. Godolphin, Maha Hussain +15 more

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

European Urology Oncology(2024)10.1016/j.euo.2024.03.001

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo +17 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216

European Urology Oncology(2024)10.1016/j.euo.2024.10.013

N/A

0DataRank · unranked

2 citations

Yeonjung Jo, Arshit Narang, Melissa Plets, Chadi Hage Chehade, Georges Gebrael +10 more

Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention Trial

The Journal of Urology(2024)10.1097/ju.0000000000003937

N/A

0DataRank · unranked

0 citations

Phyllis J. Goodman, Catherine M. Tangen, M. Scott Lucia, Ian M. Thompson, Cathee Till

Prostate-specific Antigen Screening in Limbo: How Low Should We Go?

European Urology(2024)10.1016/j.eururo.2024.05.005

N/A

0DataRank · unranked

0 citations

Ian M. Thompson

Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer

European Urology(2025)10.1016/j.eururo.2025.03.023

N/A

0DataRank · unranked

15 citations

Parminder Singh, David J. McConkey, M. Scott Lucia, Vadim S. Koshkin, Kelly Stratton +16 more

Joint Biochemical and Genetic Prostate Cancer Risk Stratification

The Journal of Urology(2025)10.1097/ju.0000000000004859

N/A

0DataRank · unranked

0 citations

Roni Haas, Christine Ibilibor, Jonathan Gelfond, Martin Goros, Teresa L. Johnson‐Pais +6 more

Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial

Cancer Prevention Research(2020)10.1158/1940-6207.capr-19-0450

N/A

0DataRank · unranked

9 citations

İbrahim Kulaç, Berrak Gümüşkaya, Javier Baena-Del Valle, Inés Benedetti, Fan Pan +13 more

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5022

N/A

0DataRank · unranked

55 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, Scott Lucia, William T. Lowrance +11 more

A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer

Journal of Geriatric Oncology(2020)10.1016/j.jgo.2020.07.014

N/A

0DataRank · unranked

3 citations

Ingrid J. Hall, Judith Lee Smith, Donatus U. Ekwueme, Catherine R. Fedorenko, Karma L. Kreizenbeck +4 more

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5506

N/A

0DataRank · unranked

4 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +14 more

Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5028

N/A

0DataRank · unranked

4 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +11 more

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.106

N/A

0DataRank · unranked

0 citations

Mai T. Duong, Catherine M. Tangen, Neeraj Agarwal, Heather H. Cheng, Nicholas J. Vogelzang +5 more

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5523

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +9 more

Contacts with Macrophages Promote an Aggressive Nanomechanical Phenotype of Circulating Tumor Cells in Prostate Cancer

Cancer Research(2021)10.1158/0008-5472.can-20-3595

N/A

0DataRank · unranked

48 citations

Alessandra Cunsolo, Meizhen Chen, Yusheng Qian, Chun-Lin Lin, Chia-Nung Hung +9 more

Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies

American Journal of Clinical Nutrition(2021)10.1093/ajcn/nqab217

N/A

0DataRank · unranked

39 citations

Fangcheng Yuan, William Wheeler, Beben Benyamin, Mitchell J. Machiela, Alan A. Arslan +74 more

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3587

N/A

0DataRank · unranked

34 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +16 more

Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer

Cancer(2021)10.1002/cncr.33911

N/A

0DataRank · unranked

8 citations

Kehao Zhu, Yingye Zheng, Lisa F. Newcomb, Jeannette M. Schenk, James D. Brooks +15 more

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4541

N/A

0DataRank · unranked

27 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, Scott Lucia, William T. Lowrance +10 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5001

N/A

0DataRank · unranked

7 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara +15 more

A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry

European Urology(2022)10.1016/j.eururo.2021.12.023

N/A

0DataRank · unranked

48 citations

Raymond W. Hughley, Aaron Pfennig, Ujani Hazra, C.P.S. Fan, Peggy Wan +95 more

Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial

Frontiers in Oncology(2022)10.3389/fonc.2021.808715

N/A

0DataRank · unranked

12 citations

Anna E. Płatek, Cathee Till, Phyllis J. Goodman, Catherine M. Tangen, Elizabeth A. Platz +5 more

Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance

Cancer Medicine(2022)10.1002/cam4.4778

N/A

0DataRank · unranked

10 citations

Lisa F. Newcomb, Kehao Zhu, Yingye Zheng, Hilary Boyer, Navonil De Sarkar +16 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps402

N/A

0DataRank · unranked

17 citations

Catherine M. Tangen, Abhishek Tripathi, Brian Shuch, Sumanta K. Pal, Pedro C. Barata +9 more

National impact of the COVID-19 pandemic on clinical trial staff attrition: Results of the SWOG Cancer Research Network Survey of Oncology Research Professionals.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11049

N/A

0DataRank · unranked

12 citations

Connie M. Szczepanek, Daniel P. Petrylak, Dana B. Sparks, Catherine M. Tangen, Primo N. Lara +3 more

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.536

N/A

0DataRank · unranked

5 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

Ian M. Thompson

Indexed papers

Top data-sharing exemplar

Papers